ReviewJournal of cardiovascular pharmacology2018
Levosimendan in Acute and Advanced Heart Failure: An Appraisal of the Clinical Database and Evaluation of Its Therapeutic Applications.
Review in Journal of cardiovascular pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 40 citations in OpenAlex.
- Efficacy of levosimendan for acute decompensated heart failure with preserved ejection fraction in the elderly: a single-center retrospective analysis.BMC cardiovascular disorders · 2025Article
- Lowering B-type natriuretic peptide levels and increasing cardiac function: the role of levosimendan in the treatment of heart failure.The Journal of international medical research · 2025Article
- Levosimendan's Effects on Length-Dependent Activation in Murine Fast-Twitch Skeletal Muscle.International journal of molecular sciences · 2024Article
- Heart Failure with Preserved Ejection Fraction: a Pharmacotherapeutic Update.Cardiovascular drugs and therapy · 2023Review
- Therapeutic Development of Levosimendan in Acute and Advanced Heart Failure: A Systematic Review.Cureus · 2023Review
- A Holistic View of Advanced Heart Failure.Life (Basel, Switzerland) · 2022Review
- The Adenylate Cyclase Activator Forskolin Potentiates the Positive Inotropic Effect of the Phosphodiesterase Inhibitor Milrinone But Not of the Calcium Sensitizer Levosimendan nor of Its Hemodynamically Active Metabolites: An Apparent Conundrum.Journal of cardiovascular pharmacology · 2022Article
- Echocardiography and impedance cardiography as determinants of successful slow levosimendan infusion in advanced older heart failure patients.Journal of geriatric cardiology : JGC · 2021Article
- Effects of Levosimendan on Systemic Perfusion in Patients with Low Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) Score: Experience from a Single Center in Taiwan.Acta Cardiologica Sinica · 2021Article
- MitraClip Implantation for Functional Mitral Regurgitation With Coaptation Gap Facilitated by Levosimendan Treatment.JACC. Case reports · 2020Article
- Short-term treatments for acute cardiac care: inotropes and inodilators.European heart journal supplements : journal of the European Society of Cardiology · 2020Article
- Optimizing fluorine labelling forJournal of biomolecular NMR · 2020Article
- Haemodynamic Balance in Acute and Advanced Heart Failure: An Expert Perspective on the Role of Levosimendan.Cardiac failure review · 2019Review
- Use of Levosimendan in Intensive Care Unit Settings: An Opinion Paper.Journal of cardiovascular pharmacology · 2019Review
- Repetitive levosimendan treatment in the management of advanced heart failure.European heart journal supplements : journal of the European Society of Cardiology · 2018Article
- The CardioMEMS system in the clinical management of end-stage heart failure patients: three case reports.BMC cardiovascular disorders · 2018Article
- Levosimendan in Advanced Heart Failure: Where Do We Stand?Journal of cardiovascular pharmacology · 2018Article
- The Use of Low-Dose Intermittent Levosimendan Infusion Therapy as Bridge-to-Left Ventricular Assist Device in Advanced Chronic Heart Failure Secondary to Isolated Cardiac Sarcoidosis.Heart views : the official journal of the Gulf Heart AssociationArticle
Corrections and comments
- Commented on by
Authors and funding
12 authors at 11 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of inotropes for correcting hemodynamic dysfunction in patients with congestive heart failure has been described over many decades. However, negative or insufficient data have been collected regarding the effects of cardiac glycosides, catecholamines, and phosphodiesterase inhibitors on quality of life and survival. More recently, the calcium sensitizer and potassium channel-opener levosimendan has been proposed as a safer inodilator than traditional agents in some heart failure settings, such as advanced heart failure. At the 2017 annual congress of the Heart Failure Association of the European Society of Cardiology (Paris, April 30-May 2), a series of tutorials delivered by lecturers from 8 European countries examined how to use levosimendan safely and effectively in acute and advanced heart failure. The proceedings of those tutorials have been collated in this review to provide an expert perspective on the optimized use of levosimendan in those settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.